Literature DB >> 6280604

Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus.

H Machida, A Kuninaka, H Yoshino.   

Abstract

Thymidine analogs highly active against herpes simplex virus were compared in their inhibitory action against seven strains of varicella-zoster virus by a plaque reduction assay. E-5-Bromovinyl-arabinosyluracil (BV-ara-U) was most active, followed by E-5 chlorovinyl-arabinosyluracil, E-5-bromovinyl-2'-deoxyuridine (BV-dUrd), 2'-fluoro-5-methyl-arabinosyluracil, 2'-fluoro-5-iodo-arabinosylcytosine, arabinosylthymine, 5-vinyl-arabinosyluracil, acycloguanosine, and 5-iodo-2'-deoxyuridine, in order to decreasing activity. BV-ara-U was more than 10 times as active as BV-dUrd and almost completely inhibited plaque development of five strains of varicella-zoster virus at a concentration as low as 1 ng/ml.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6280604      PMCID： PMC181891          DOI： 10.1128/AAC.21.2.358

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

2.  Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.

Authors:  K A Watanabe; U Reichman; K Hirota; C Lopez; J J Fox
Journal:  J Med Chem       Date:  1979-01       Impact factor: 7.446

3.  Herpes zoster in children with cancer.

Authors:  S Feldman; W T Hughes; H Y Kim
Journal:  Am J Dis Child       Date:  1973-08

4.  Varicella-Zoster infection in patients with cancer.

Authors:  S Schimpff; A Serpick; B Stoler; B Rumack; H Mellin; J M Joseph; J Block
Journal:  Ann Intern Med       Date:  1972-02       Impact factor: 25.391

5.  Growth inhibition by acycloguanosine of herpesviruses isolated from human infections.

Authors:  C S Crumpacker; L E Schnipper; J A Zaia; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

6.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

7.  In vitro antiherpesviral activity of 5-alkyl derivatives of 1-beta-D-arabinofuranosyluracil.

Authors:  H Machida; S Sakata; A Kuninaka; H Yoshino; C Nakayama; M Saneyoshi
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

8.  Herpes zoster and varicella infections in children with Hodgkin's disease: an analysis of contributing factors.

Authors:  F Reboul; S S Donaldson; H S Kaplan
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

9.  Antiherpesviral activity and inhibitory action on cell growth of 5-alkenyl derivatives of 1-beta D-arabinofuranosyluracil.

Authors:  H Machida; A Kuninaka; H Yoshino; K Ikeda; Y Mizuno
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  Differential effect of arabinofuranosylthymine of the replication of human herpesviruses.

Authors:  R L Miller; J P Iltis; F Rapp
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103
View more
  9 in total

1.  Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

Authors:  J Balzarini; C Zhu; E De Clercq ; M J Pérez-Pérez; C Chamorro; M J Camarasa; A Karlsson
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Use of an enzyme-linked immunosorbent assay performed directly on fixed infected cell monolayers for evaluating drugs against varicella-zoster virus.

Authors:  F E Berkowitz; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

4.  Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.

Authors:  T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

5.  Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds.

Authors:  S R Preblud; A M Arbeter; E A Proctor; S E Starr; S A Plotkin
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs.

Authors:  H Machida
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

7.  Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication.

Authors:  J C Lin; H Machida
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

8.  Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2.

Authors:  T Suzutani; H Machida; T Sakuma; M Azuma
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

9.  Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  E De Clercq; J Descamps; J Balzarini; T Fukui; H S Allaudeen
Journal:  Biochem J       Date:  1983-05-01       Impact factor: 3.857
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.